Erratum to: Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics
https://doi.org/10.1186/1756-0500-7-652
© Hariani et al.; licensee BioMed Central Ltd. 2014
Received: 9 September 2014
Accepted: 10 September 2014
Published: 17 September 2014
The original article was published in BMC Research Notes 2014 7:360
Correction
After publication of this work [1], it has come to our attention that there is an error in the author list of the initial version of this manuscript; rather than Ernest J Lam, the second author of the manuscript should be listed as Ernest T Lam.
We publish this correction to update the author list with this information. The correct author list is as follows:
Gunjan D Hariani, Ernest T Lam, Tammy Havener, Pui-Yan Kwok, Howard L McLeod, Michael J Wagner and Alison A Motsinger-Reif
This error was introduced during the final production process and the editors of BMC Research Notes apologise for any inconvenience caused.
Notes
Authors’ Affiliations
References
- Hariani GD, Lam EJ, Havener T, Kwok PY, McLeod HL, Wagner MJ, Motsinger-Reif AA: Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics. BMC Res Notes. 2014, 7: 360-10.1186/1756-0500-7-360.PubMedPubMed CentralView ArticleGoogle Scholar
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
